NASSCOM Submits Comments to Ministry of Health and Family Welfare on the Draft Drugs, Medical Devices & Cosmetics Bill, 2022

Terms of use

Terms of Use

The use of this site and the content contained therein is governed by the Terms of Use. When you use this site you acknowledge that you have read the Terms of Use and that you accept and will be bound by the terms hereof and such terms as may be modified from time to time.

All text, graphics, audio, design and other works on the site are the copyrighted works of nasscom unless otherwise indicated. All rights reserved.
Content on the site is for personal use only and may be downloaded provided the material is kept intact and there is no violation of the copyrights, trademarks, and other proprietary rights. Any alteration of the material or use of the material contained in the site for any other purpose is a violation of the copyright of nasscom and / or its affiliates or associates or of its third-party information providers. This material cannot be copied, reproduced, republished, uploaded, posted, transmitted or distributed in any way for non-personal use without obtaining the prior permission from nasscom.
The nasscom Members login is for the reference of only registered nasscom Member Companies.
nasscom reserves the right to modify the terms of use of any service without any liability. nasscom reserves the right to take all measures necessary to prevent access to any service or termination of service if the terms of use are not complied with or are contravened or there is any violation of copyright, trademark or other proprietary right.
From time to time nasscom may supplement these terms of use with additional terms pertaining to specific content (additional terms). Such additional terms are hereby incorporated by reference into these Terms of Use.

Disclaimer

The Company information provided on the nasscom web site is as per data collected by companies. nasscom is not liable on the authenticity of such data.
nasscom has exercised due diligence in checking the correctness and authenticity of the information contained in the site, but nasscom or any of its affiliates or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this site. The information from or through this site is provided "as is" and all warranties express or implied of any kind, regarding any matter pertaining to any service or channel, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement are disclaimed. nasscom and its affiliates and associates shall not be liable, at any time, for any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communications line failure, theft or destruction or unauthorised access to, alteration of, or use of information contained on the site. No representations, warranties or guarantees whatsoever are made as to the accuracy, adequacy, reliability, completeness, suitability or applicability of the information to a particular situation.
nasscom or its affiliates or associates or its employees do not provide any judgments or warranty in respect of the authenticity or correctness of the content of other services or sites to which links are provided. A link to another service or site is not an endorsement of any products or services on such site or the site.
The content provided is for information purposes alone and does not substitute for specific advice whether investment, legal, taxation or otherwise. nasscom disclaims all liability for damages caused by use of content on the site.
All responsibility and liability for any damages caused by downloading of any data is disclaimed.
nasscom reserves the right to modify, suspend / cancel, or discontinue any or all sections, or service at any time without notice.

For any grievances under the Information Technology Act 2000, please get in touch with Grievance Officer, Mr. Anirban Mandal at data-query@nasscom.in.

New

See all

No notification found.

NASSCOM Submits Comments to Ministry of Health and Family Welfare on the Draft Drugs, Medical Devices & Cosmetics Bill, 2022

Devika Agarwal

@DevikaAgarwal

August 30, 2022

Public Policy

256

On 8^th July, 2022 the Ministry of Health and Family Welfare (MoHFW) released a draft of the Drugs, Medical Devices and Cosmetics Bill, 2022 (‘draft Bill’) for public consultation. The objective behind the draft Bill was to review obsolete laws and update existing laws to keep pace with changing needs, times and technology. NASSCOM submitted its feedback to the MoHFW on the draft Bill on 22^nd August, 2022.

The main recommendations made by NASSCOM are as follows:

Medical devices should be treated distinctly from drugs: The draft Bill defines ‘medical devices’ separately, instead of including them within the definition of ‘drug’. This is a welcome change to the existing law. However, there is a concern that medical devices may continue to be regulated in a manner similar to drugs in practice. We recommend certain measures to address this concern, such as the creation of a separate wing within the Central Drugs Standard Control Organisation (CDSCO) or a separate body for regulating medical devices. Further, the qualifications of Medical Device Officers may be prescribed as Bachelors in Engineering in any relevant field to avoid non-qualified Drug Inspectors from being appointed as Medical Device Officers.
Adoption of international best practices will promote the medical device industry: The government may adapt best practices prevalent in other jurisdictions for regulation of medical devices in India. For instance, ‘contract manufacturers’, should be excluded from the definition of ‘manufacturer’ in the context of medical devices. Currently, contract manufacturers of medical devices are assigned legal liability, which makes such manufacturers averse to entering into manufacturing contracts, thereby adversely impacting medical device start-ups which rely on such contract manufacturers. Further, the government should only prescribe standards related to the performance and safety of medical devices, instead of technical standards.
Post-market surveillance of medical devices should be mandated: The government should take measures to ensure post-market surveillance of medical devices in the interest of consumer safety. Similar to the Food and Drug Administration (FDA) in the US, the government could mandate user facilities (including hospitals and nursing homes) to report any adverse event involving medical devices. This information should be made publicly available, similar to the Manufacturer and User Facility Device Experience (MAUDE) database.
Public consultation should be held prior to making rules under the Draft Bill: The government should release the draft rules made inter alia under sections 83(2)(l) and 118(2)(r) (which empower the Central Government to make rules under Chapters IV and V of the draft Bill) for public consultation and provide sufficient time to the industry to implement the rules once they are finalised.
The draft Bill should be aligned with the existing Medical Devices Rules, 2017 (MDR): The standards prescribed for medical devices under section 126 of the draft Bill should link back to the provisions of the MDR which require medical devices to conform to the standards formulated by the Bureau of Indian Standards (BIS), or alternatively, the International Organisation for Standardisation (ISO)/ International Electro Technical Commission (IEC) standards. Similarly, the government may exempt medical devices from undergoing clinical investigation (in line with Rule 63 of the MDR).
As a general rule, the licensing authority should first issue an improvement notice in case of non-compliance: In cases of non-compliance in the first instance, the licensing authority should issue an improvement notice, except in certain specific circumstances.
Fines should not be recovered as arrear of land revenue: Section 64 of the draft Bill (power to recover certain amount as arrear of land revenue) should be deleted as it violates the principle of natural justice.
The draft Bill should provide certain definitions: The draft Bill should provide definitions for ‘registered medical practitioner’ in the context of allopathy and define ‘prescription’. This would bring about clarity for e-commerce marketplaces on who may prescribe allopathic drugs, and what constitutes a valid prescription.
The requirement to capture batch number of AYUSH drugs will facilitate recall of such drugs: The draft Bill should mandate that the batch number should be captured in the sales invoice for AYUSH drugs, to implement the recall process for AYUSH drugs. The draft Bill should also empower the Central Controlling Authority or the State Licensing Authority to recall an allopathic drug or medical device which is unsafe for use.
The records should be allowed to be maintained or furnished in electronic format: To facilitate the ease of doing business, records should be allowed to be maintained in electronic format (under section 43 of the draft Bill). Further, online pharmacies should be allowed to digitise the prescription and provide a digital copy in consumer accounts, for better traceability and record-keeping.

[The full-text of NASSCOM’s recommendations is appended. Kindly contact dagarwal@nasscom.in and sudipto@nasscom.in for further details].

Health Tech medical devices e-pharmacies Start-ups e-commerce

Disclaimer

That the contents of third-party articles/blogs published here on the website, and the interpretation of all information in the article/blogs such as data, maps, numbers, opinions etc. displayed in the article/blogs and views or the opinions expressed within the content are solely of the author's; and do not reflect the opinions and beliefs of NASSCOM or its affiliates in any manner. NASSCOM does not take any liability w.r.t. content in any manner and will not be liable in any manner whatsoever for any kind of liability arising out of any act, error or omission. The contents of third-party article/blogs published, are provided solely as convenience; and the presence of these articles/blogs should not, under any circumstances, be considered as an endorsement of the contents by NASSCOM in any manner; and if you chose to access these articles/blogs , you do so at your own risk.

Download Attachment

Devika Agarwal

Call for Inputs: SEBI's consul...

Swapnil